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. It has two active sites, which catalyse the obligate two-electron reduction of quinones, quinone epoxides and quinone-imines to hydroquinones [2] . The enzyme is unusual in that it has the capacity to utilise both the pyrimidine nucleotides NADH and NADPH, without preference, as reducing co-substrates [3] . The catalytic cycle of NQO1 functions via a "ping-pong" mechanism in two distinct steps: hydride transfer from the NAD(P)H to the FAD cofactor, followed by release of NAD(P) + and hydride transfer from the reduced cofactor to the quinone substrate [4] . This two electron reduction mechanism also means that NQO1 has antioxidant properties, as it will prevent reduction of quinones by one-electron reductases. The latter would cause the formation of semiquinones with concomitant formation of reactive oxygen species [2] .
An additional function of NQO1 is its clear ability to act as a chaperone protein. It has been described as the "gate keeper" of the 20S proteosome [5] and regulates the degradation of certain onco-proteins such as p53, p73α and ornithine decarboxylase and proteins important in the regulation of mRNA translation [6, 7] . The ability of NQO1 to stabilize proteins is dependent upon NADH [8] which suggests that the binding of the enzyme to its client protein(s) is most efficient when the protein FAD is in its reduced form. The anticoagulant dicoumarol (3,3'-methylenebis(4-hydroxycoumarin), has historically been regarded as the most potent inhibitor of NQO1 [9] ; it acts through competitive binding with NAD(P)H and 4 prevents the two-electron transfer to FAD from occurring [10] . Hence, addition of dicoumarol to cells has been shown to target p53 and other client proteins for degradation [6-8, 11, 12] .
NQO1 is constitutively expressed in a variety of tissues throughout the body, but is overexpressed in many solid tumours [13, 14] . These observations have made NQO1 a potential target for the activation of certain bioreductive anticancer agents [15] such as mitomycin C [16] , EO9 (5-aziridinyl-3-hydroxymethyl-2-(3-hydroxyprop-1-enyl)-1-methylindole-4,7-dione) [17] , streptonigrin [18] , RH1 ((2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone) [19] and β-lapachone [20] .
Dicoumarol is often used as a pharmacological inhibitor to study the function of NQO1 in cells. This has not only been to establish the importance of the enzyme for the activation of bioreductive drugs [21, 22] , but also to identify the importance of NQO1 for determining protein stability [23] . However, the actions of dicoumarol are compromised by extensive protein binding [24] and confounding "off-target" effects such as mitochondrial uncoupling [25, 26] and the increased production of intracellular superoxide [27, 28] . These off-target effects can interfere with the interpretation of the function of NQO1 in cells. An example is where dicoumarol-induced production of superoxide was thought to be the basis for toxicity towards pancreatic cancer cells and this phenomena was considered to be NQO1 dependent [29, 30] . However, different research group have subsequently presented data to show that these observations are not solely due to the inhibition of NQO1 but more importantly due to other properties of dicoumarol [28, 31, 32] . Thus, it is therefore of interest to develop novel inhibitors of NQO1 which retain the NQO1 inhibitory potency of dicoumarol but lack its unfavourable off-target effects.
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The synthesis of a series of novel substituted coumarin-based compounds with improved inhibitory potency in both isolated enzyme systems and cells has recently been reported [28, 33, 34] . This series of compounds have now been evaluated for their "off-target" effects when compared with dicoumarol. This paper provides an evaluation of the toxicity of these compounds in vitro, effects on cell cycle, and their abilities to cause apoptosis and generate superoxide. The major aim of the study was to identify compounds that may be more pharmacologically acceptable than dicoumarol; these will be compounds that have a similar or greater NQO1 inhibitory potency to dicoumarol, but have a lower level of cellular toxicity and fewer off-target effects.
Materials and Methods

Reagents, chemicals and NQO1 inhibitors
Unless otherwise stated, all reagents and chemicals were supplied by Sigma Aldrich (Poole, Dorset, UK). The NQO1 inhibitors have been previously described [28, 33, 34] . They comprise two series of substituted coumarins. The first includes a set of substituted dicoumarol analogues (the symmetric, S series, where dicoumarol is designated S1). The second group of compounds have one of the 4-hydroxycoumarol rings replaced by an aromatic ring system (the asymmetric, AS series). Structures are given in Figure 1 and Table   1 . The compounds were dissolved in either DMSO (Fisher Scientific, Leicestershire, UK) or 0.13M NaOH (VWR, Leicestershire, UK) to give a final concentration of 25mM. cells which had been stably transfected with NQO1 (designated-DTD) [35] , puromycin was added to the culture medium at a concentration of 5µg/ml in order to maintain selection.
Determining the activity of NQO1 in cells
Cells at a concentration of 1.5 x 10 5 were seeded into 10cm dishes and left to reach approximately 70% confluence. They were then washed in PBS (OXOID, Hampshire, UK) and scraped into phosphate buffer (pH 7.5) containing 5µM FAD and 250mM sucrose. The cells were sonicated twice for 5 seconds on ice, centrifuged at 13,000rpm (16,200g) for 15 minutes at 4C, and the supernatants collected and stored at -80C. Protein concentrations were determined using the Bicinchoninic acid (BCA) protein assay [36] . The assay for NQO1 enzyme activity has been described previously [28] . Briefly, 10µl of cell lysate was mixed with 490µl of 50mM phosphate buffer at pH 7.5 containing 200μM NADH, 70μM cytochrome c and 20μM menadione. Reactions were carried out at 25°C and cytochrome c reduction was followed at 550nm in a Beckman DU650 spectrophotometer. Dicoumarol 7 (100µM) was added to a parallel reaction mixture and the difference in the rates of reaction in the presence and absence of dicoumarol was then used to define the activity of NQO1 in the cellular lysates.
Assays of toxicity
The MTT proliferation assay [37] was used as a surrogate measure of the toxicity of the dicoumarol analogues. Cells were seeded at 7.5 x 10 3 cells/well into 96-well plates and were exposed to increasing concentrations of dicoumarol (S1) or each inhibitor from the S and AS series for 96 hours. The number of surviving cells was then determined using the MTT assay.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was dissolved in sterile PBS and added to the wells at a final concentration of 1.5mM. Cells were incubated with MTT for 4 hours, at which time the resulting formazan crystals were solubilised with DMSO and absorbance read at 540nm. Values of IC 50 were calculated as the drug concentration required to reduce optical density by 50% relative to vehicle treated control cells.
In some experiments, A549 or MIA PaCa-2 cells were treated with EO9 (Apaziquone, synthesized in-house) with and without various non-toxic concentrations of the S and AS compounds for 3 hours. EO9 and the compounds were then removed and cells left in growth medium for 96 hours prior to addition of MTT for assessment of toxicity. As this has been described in detail previously [34] , the ability of the putative enzyme inhibitors to protect against the toxicity of EO9 in cells is a surrogate measure for their ability to inhibit cellular NQO1. to report the formation of intracellular superoxide [38] . The oxidized product, 2-hydroxyethidium, was excited by blue light (488nm, argon laser) and fluorescence was measured using a 613/20 bandpass filter. The use of dihydroethidium is considered to be a relatively specific method for measuring superoxide [38] . However, it can be oxidized by other agents such as hydrogen peroxide in the presence of haem containing proteins [39] .
These oxidation reactions can result in the production of different oxidation products with excitation and emission spectra overlapping with that of 2-hydroxyethidium [26] . Thus, to confirm that oxidation of dihydroethidium occurred via reaction with superoxide, experiments were carried out in the presence of ambroxol (2-amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl] benzylamine). Ambroxol is a, so-called, superoxide, dismutase mimetic and has been used previously [26, 40] to confirm oxidation reactions occurring via superoxide.
In all experiments, cells were exposed to 50µM menadione as a positive control for generation of superoxide.
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Cell cycle analysis
Cells were seeded into 10cm dishes at a concentration of 1. 
Western blot analysis of apoptotic markers
Exponentially growing cells were seeded into 6-well plates at a concentration of 1. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 sodium pyrophosphate; and 1mg/ml Protease Inhibitor Cocktail tablet (Roche, Hertfordshire, UK). Samples were sonicated on ice and the protein concentration was estimated using the BCA protein assay. Protein (40µg) was loaded for each sample, resolved on a 10%
polyacrylamide gel and then transferred to a polyvinylidene (PVDF) membrane (Millipore, Hertfordshire, UK). Immunoblotting was carried out using a 1:1000 dilution of the cleaved PARP antibody (New England Biolabs, HertfordshireUK; anti-rabbit) or a 1:40000 dilution of the actin antibody. Primary antibodies were detected using the correct horse radish peroxidise (HRP)-conjugated secondary antibody, and the ECL detection system (GE Healthcare, Buckinghamshire, UK) was used to visualise the respective bands.
Results
Novel analogues of dicoumarol (S1) have been synthesized (the S and AS series in Figure 1 and Table 1 ) and shown to be potent inhibitors of recombinant NQO1 [33] . These molecules also show potent activity for inhibiting the activity of NQO1 in HT29 cells, with potency correlating well with that observed when measuring inhibition of recombinant enzyme in the presence of BSA [34] . These published data are given in Table 1 . Inhibition of cellular NQO1
was characterized by the ability of the S and AS compounds to inhibit the cytotoxic activity of the indolequinone EO9, an agent known to be exquisitely dependent on NQO1 for toxicity under aerobic conditions [21, 22] . Table 1 also shows the ability of the S and AS compounds to inhibit NQO1 in A549 and MIA PaCa-2 cells. Using the EO9 toxicity end-point as a surrogate measure of NQO1 inhibition, it is apparent that S3 is the most active compound in each cell line, being 2.5 to 10-fold more potent than dicoumarol for protecting against EO9
toxicity. In the S series, S10 and S13 are up to 2-fold more efficient than dicoumarol (S1), whereas the remaining compounds are less effective. On the contrary, in the AS series, all the 11 compounds are at least as efficient as dicoumarol, with some (AS2 and AS14) showing 2-to 4-fold greater potency in the different cell lines. With the knowledge that these compounds are functionally active as inhibitors of NQO1 in cells, it is now possible to assess any "offtarget" activity and relate this to NQO1 inhibition.
The toxicity of the dicoumarol analogues in cell lines expressing varying levels of NQO1
The activity of NQO1 in the cell lines used in the present work is given in Table 2 . Cell lines were chosen to have varying NQO1 activity. The MDA-MB-231, MDA-MB-468 and T47D
WT cells are null for NQO1 due to a homozygous polymorphism (NQO1*2/*2) [41, 42, 43] .
Each of these cell lines have been genetically engineered to stably overexpress functional NQO1 [35] . In order to evaluate any contribution of p53, the HCT116 p53 +/+ and -/-pair of cell lines were used [44] . The values for enzyme activity given in Table 2 previously, the values reported here compare extremely well [17] . It has been suggested [30] that the toxicity of dicoumarol is mediated by its ability to inhibit NQO1 thereby increasing cellular exposure to reactive oxygen species. Therefore, the toxicity of dicoumarol (S1) and analogues from the S and AS series were evaluated in all the cell lines. Values of IC 50 , the concentration required to reduce proliferation by 50%, are given in Table 3 . Dicoumarol is consistently one of the most toxic compounds in all of the cell lines and it is clear that neither NQO1 nor p53-status plays a role in determining toxicity. There also appears to be no relationship between the toxicity induced by the compounds and their ability to inhibit NQO1enzymatic activity (Table 1) .
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Production of intracellular superoxide
Dicoumarol has been shown to dose-dependently increase the production of superoxide in MIA PaCa-2 pancreatic cancer cells [27] . This result was recapitulated here using flow cytometry to measure the superoxide-mediated oxidation of dihydroethidium to 2-hydroxyethidium. Figure 2 shows fluorescence intensity histograms acquired following treatment of MIA PaCa-2 cells with increasing concentrations of dicoumarol (S1) for 4 hours.
In all experiments, 50μM menadione was used as a positive control for superoxide production [45] . From the fluorescence intensity profile obtained for untreated control cells, the R3 region is defined as that containing cells with increased fluorescence. Clearly, treatment with dicoumarol results in a dose-dependent increase in the number of fluorescent cells, which is consistent with previous data [27] suggesting it was dicoumarol-induced superoxide formation that caused the increased intracellular fluorescence. To confirm this, the superoxide dismutase mimetic, ambroxol, was added to the cells exposed to dicoumarol. There is substantial variation in the ability of the compounds to generate superoxide and there appears to be no relationship with the ability of the different compounds to inhibit NQO1.
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However, interestingly, the compounds in the S series that contain a methoxy group in the coumarin ring (S3, S4, S5 and S11) and those in the AS series that contain the simpler Xsubstituent (AS3, AS6 and AS14) show substantially lower induction of superoxide than dicoumarol (S1) and the other compounds. This is reflected in an apparent correlation between superoxide production and the ability of the compounds to inhibit the proliferation of MIA PaCa-2 cells as measured by the MTT assay ( Figure 4 ).
In order to confirm whether the phenomenon of intracellular superoxide production is not Clearly, there is no significant difference in the generation of intracellular superoxide between the two cell lines for any of the compounds. It is also apparent that the same lack of dependence on NQO1 for superoxide production is seen for menadione (also shown in Figure   5 ).
Effects on cell cycle progression and induction of apoptosis
It has been shown previously that dicoumarol can promote the growth of HL-60 cancer cells via cell cycle perturbation [46] . In order to determine the effects of dicoumarol and the S and AS analogues on cell cycle progression, MIA PaCa-2 cells were exposed to 200µM of each of the compounds for 24 hours before staining with propidium iodide for cell cycle analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 (Table 1) . Finally, to confirm that there was no link between induction of apoptosis and cellular levels of NQO1, cell cycle analysis of the MDA-MB-231
WT and DTD cells was made following treatment for 24 hours with 200µM of dicoumarol (S1). The proportion of cells in the sub-G1 region following treatment is given in the M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 Supplementary data Figure 2 and these results clearly show that the cellular NQO1 status has no influence on the number of cells in sub-G1.
Discussion
The purpose of this work has been to identify compounds that are potent inhibitors of NQO1 but with superior pharmacological acceptability than the conventional inhibitor, dicoumarol.
A series of substituted coumarins has been synthesized ( Figure 1 and Table 1 ) and many of these have equivalent or greater potency for inhibiting NQO1 than dicoumarol [33, 34] .
Further, these agents can also inhibit the functional activity of NQO1 in intact HT29 colon cancer, A549 non small cell lung cancer and MIA PaCa-2 pancreatic cancer cell lines [34] A number of these compounds (S3, S10, S13, AS2 and AS14) are consistently more potent than dicoumarol, which suggests they may have general applicability as NQO1 inhibitors in cells.
It is known that dicoumarol has a variety of "off-target" effects that can confound interpretation of its action as an inhibitor of NQO1 in cells. Therefore, to establish the potential pharmacological usefulness of the substituted coumarins, experiments have been carried out to determine their toxicity in a large panel of cell lines, their ability to generate superoxide and their ability to cause apoptosis.
In the toxicity studies reported here, there is no relationship between the ability of the as these cells were used by Du, Cullen and colleagues [27, 29, 30, 46] who initially proposed that dicoumarol generated superoxide via an NQO1-mediated mechanism. In the S series, compounds such as S10 and S13 are as efficient, if not more so, than dicoumarol for generating superoxide. These compounds are effective for inhibiting NQO1 in cells, but so is S3, and this compound generates little if any superoxide. A molecular feature of the compounds in the S series that do not generate superoxide is that they all contain a methoxy group in the coumarin ring. For the AS series, these compounds generally cause formation of superoxide. However, there are exceptions, with AS3 and AS6 generating substantially less superoxide than similar concentrations of dicoumarol; additionally, AS14, which is a more efficient inhibitor of NQO1 in cells than dicoumarol, generates little if any superoxide. Taken together with results showing similar superoxide production in isogenic cells expressing differing levels of NQO1 (MDA-MB-231 cells) and those in previous work reported by our group [28] , and others [31, 32] , these data strongly suggest that cellular NQO1 plays little if any role in the generation of superoxide in cells following treatment with dicoumarol and its analogues. However, the generation of superoxide may be the basis for the toxicity of the coumarin analogues as is suggested by the correlation shown in Figure 4 . Interestingly, the relationship between superoxide production and apoptosis is less apparent, although it is quite clear that those compounds generating the greater amount of superoxide are those that produce most apoptosis.
Other off-target effects associated with dicoumarol include extensive protein binding and mitochondrial uncoupling. Protein binding has previously been shown [33] to be much Thus, we have provided a firm basis for development of compounds to evaluate the impact of NQO1 inhibition in cells.
Using gene knockout technology it has been shown that loss of NQO1 is associated with reduced p53 stability [48, 49] and changes in NFκB signalling [50] . Treatment of cells with dicoumarol can also cause degradation of p53 and other onco-proteins in a process that is mediated by NQO1. There is good evidence to show that transient disruption of p53 during and after irradiation can protect against radiation damage [51, 52] . Thus, there may well be substantial scope for developing NQO1 inhibitors for therapeutic use [34] . In summary, it has been shown that there are a number of compounds that act as potent inhibitors of NQO1 and, beneficially, they lack the off-target effects associated with dicoumarol.
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